Date updated:04-26-2007
There are many companies researching treatments and cures for this degenerative disorder of the central nervous system that impairs motor skills and speech. Here are some of them.

-
TEVA
Teva Pharmaceutic - $53.16
- -0.21%
- $53.70
Teva Pharmaceutical Industries Ltd. (TEVA), an Israeli based company which was founded in 1901, develops and manufactures a variety of pharmaceuticals. They received approval from the U.S. Food and Drug Administration for AZILECT® (rasagiline tablets) as a treatment for Parkinson's disease. P/E is 54 and PEG is 1.1. The stock has been paying dividends quarterly and yields 1%.

-
CEGE
Cell Genesys - $0.36
- 0.00%
- $N/A
Cell Genesys, Inc. (CEGE) is an investor in Ceregene, which developed CERE-120, its lead program for Parkinson's disease. Earnings for CEGE are negative and the price sales ratio is an extremely high 225.

-
NVS
Novartis Ag Ads - $55.85
- +0.99%
- $55.81
Novartis AG (NVS), a very large Swiss pharmaceutical company, has developed Comtan® (entacapone), a medication for the treatment of Parkinson's Disease. P/E is 19 and the PEG is 1.5. Yield is 1.6%.

-
ACAD
Acadia Pharmaceut - $1.35
- +2.27%
- $1.34
Acadia Pharmaceuticals Inc. (ACAD), based in San Diego, is working on ACP-103 in patients with Parkinson's disease suffering from treatment-induced psychosis. Negative earnings, P/S of 53.

-
SNY
Sanofi-aventis Sa - $39.46
- +2.15%
- $39.26
Sanofi-Aventis (SNY) is the third largest pharmaceutical company in the world. It is working on SR57667B for treatment of symptoms. PE IS 23, PEG is 2.3. Yield is 2.1%.

-
SKYE
N/a - $25.55
- 0.00
- $25.55
SkyePharma plc (SKYE) developed once-daily formulation of Requip® utilizing SkyePharma's Geomatrix™ technology. Requip is used for Parkinson's treatment. No earnings, P/S is 3.5.

-
VRX
Valeant Pharma In - $33.11
- +0.79%
- $32.83
Valeant Pharmaceuticals International (VRX) markets Zelapar® [selegiline HCl] Orally Disintegrating Tablets, a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa. Forward P/E of 16.6 and a PEG of .8. Yields 1.7%.
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Top 5 Small-Cap Stocks: N...
- » Echo5Joker's Portfolio
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Jonas Elmerraji Posted on Nov. 25, 2009 With Thanksgiving fast approaching, retailers have one thing on their collective minds: Black Friday. After all, the day, whi...
By Jonas Elmerraji Posted on Nov. 24, 2009 Don’t dismiss dividends right now. While stocks may have made significant strides in the rally that’s taken hold of the m...
By Roberto Pedone Posted on Nov. 24, 2009 10 Terrific Dividend Stocks: This Barron’s article highlights 10 high-quality dividend-paying stocks for investors who’re ...
By Jonas Elmerraji Posted on Nov. 23, 2009 As well as broad-based indexes have performed in the last few months, Stockpickr's weekly Rocket Stocks list has managed to d...
A. The only one I own : SLX,
too hard pick a winner out all of them
These are some of the stocks mentioned on TheStreet.com TV recently. Click the URL below each stock to watch the videos. more
The market is closed tomorrow (11/26/2007). Here is a list of some of the companies that will report earnings on Friday (Nov. 27, 2009). For some of the companies below... more
Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more











05/01/2007 17:23 PM CDT Asked by Dark Knight 212
In addition to the companies you listed, I suggest you look at the British biotech firm Amarin (AMRN - Last Trade: 0.68 Change: -0.025). AMRN has ongoing Phase II clinical testing of Miraxion and AMR-101 both for the treatment of Parkinson's Disease.
Amarin recently dropped more than 85 percent on poor statistical results in Phase III tests of Miraxion for Huntington's disease.
After an 85% drop the stock bears watching because they have 4 other drugs in their pipeline that are on track, 29 million dollars cash, no debt and they have 30% insider and 25% institutional ownership.
Management will be providing an update to investors on the progress, plans and timelines for Amarin’s pipeline of products at two upcoming investor conferences. Rodman & Renshaw on May 15th and Banc of America on June 1st. Both of these investor presentations will be webcast so you can listen in. More information about the specifics of the webcasts will be issued in advance of each conference.
Full Disclosure: I own AMRN.
04/27/2007 03:59 AM CDT Asked by mock portfolio
I love lists like this...